AUDIENCE: Health Professional, Patient, Pharmacy
ISSUE: FDA has concluded there is an increased risk of death with febuxostat (Uloric®) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with febuxostat.
BACKGROUND:Febuxostat was FDA-approved in 2009 to treat a type of arthritis called gout in adults. Gout happens when a naturally occurring substance in the body called uric acid builds up and causes sudden attacks of redness, swelling, and pain in one or more joints. Febuxostat works by lowering uric acid levels in the blood. Gout is a chronic disease that affects approximately 8.3 million adults in the U.S.1 The number of medicines to treat gout is limited and there is an unmet need for treatments for this disease.
As a gold treatment drug for gout,it is widely used in clinical practice and has achieved results in the treatment of gout.
The other names of this product are Long-term Treatment of Gout Patients,No Adverse Reactions Safer Febuxostat,Cas 144060-53-7 With Best Price.
Looking for ideal Long-term Treatment of Gout Patients Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the No Adverse Reactions Safer Febuxostat are quality guaranteed. We are China Origin Factory of Cas 144060-53-7 With Best Price. If you have any question, please feel free to contact us.
Product Categories : Antidiabetic/Antihypertensive